When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AGLE - Aeglea Bio reports positive data for pegzilarginase in patients with ARGI-D
Aeglea BioTherapeutics Inc.
Aeglea BioTherapeutics (NASDAQ:AGLE) has presented positive 20-dose data on 14 patients from its completed Phase 1/2 trial and ongoing Phase 2 open-label extension (OLE) trial for pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D) at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism.
More news on: Aeglea BioTherapeutics, Inc., Healthcare stocks news,